Algeta to Present at Forthcoming Life Sciences Investor Conferences
(Thomson Reuters ONE) -
Oslo, Norway, 14 September 2011 - Algeta ASA (OSE: ALGETA), a company focused on
the development of novel targeted cancer therapeutics, notes that Andrew Kay,
its President & CEO, will present the Company at the following life sciences
investor conferences:
JP Morgan European Small/Mid-Cap 1x1 conference
Date: 15-16 September 2011
Venue: London, UK
Bank of America Merrill Lynch Global Healthcare conference
Date: 16 September 2011
Time: 09:55 - 10:35 BST (10:55 - 11:35 CET)
Venue: London, UK
UBS Global Life Sciences Conference
Date: 20 September 2011
Time: 10:30 - 11:00 ET (16:30 - 17:00 CET)
Venue: New York, USA
Jefferies Global Healthcare Conference in London
Date: 28 September 2011
Time: 09:20 - 10:00 BST (10:20 - 11:00 CET)
Venue: London, UK
Webcast:http://www.wsw.com/webcast/jeff62/algzf.pk/
Presentations will be available to download at www.algeta.com following these
events.
###
For further information, please contact
Andrew Kay, CEO +47 2300 7990 / +47 4840 1360 (mob)
Øystein Soug, CFO +47 2300 7990 / +47 9065 6525 (mob)
post(at)algeta.com
International media enquiries: +44 207 638 9571
Mark Swallow/David Dible/Sita Shah mark.swallow(at)citigatedr.co.uk
Citigate Dewe Rogerson
US investor enquiries: +1 646 378 2928
Jessica Lloyd jlloyd(at)troutgroup.com
The Trout Group
About Algeta
Algeta is a company focused on developing novel targeted therapies for patients
with cancer based on its alpha-pharmaceutical platform.
Algeta's lead product Alpharadin (radium-223 chloride) is a first-in-class,
highly targeted alpha-pharmaceutical under clinical evaluation to improve
survival in patients with bone metastases from advanced cancer. Its localized
action helps preserve the surrounding healthy tissue thereby limiting side-
effects.
Alpharadin is being developed under a development and commercialization
agreement with Bayer HealthCare Pharmaceuticals AG. In June 2011, a global phase
III clinical trial (ALSYMPCA) of Alpharadin to treat bone metastases in patients
with castration-resistant prostate cancer (CRPC) was stopped early after meeting
its primary endpoint of significantly improving overall survival. The US Food
and Drug Administration (FDA) has granted Alpharadin Fast Track designation for
this indication. Alpharadin is also under investigation in a phase II clinical
trial as a potential new treatment for bone metastases in endocrine-refractory
breast cancer patients, and in a phase I/IIa trial in combination with docetaxel
chemotherapy in for bone metastases CRPC patients.
The development of bone metastases represents a serious development for cancer
patients as they are associated with a dramatic decline in patient health and
quality of life, ultimately leading to death. Bone metastases represent a major
unmet medical need, occurring frequently in certain late-stage cancers, e.g.
prostate (in up to 90% patients), breast (up to 75 %) and lung (up to 40%).
Algeta is also exploring the potential of Targeted Thorium Conjugates (TTCs),
which are based on conjugating the alpha-emitter thorium-227 to targeting
molecules, as a basis of a future pipeline of tumor-targeting alpha-
pharmaceutical candidates.
The Company is headquartered in Oslo, Norway, and is listed on the Oslo Stock
Exchange (Ticker: ALGETA).
Alpharadin and Algeta are trademarks of Algeta ASA.
Forward-looking Statement
This news release contains forward-looking statements and forecasts based on
uncertainty, since they relate to events and depend on circumstances that will
occur in the future and which, by their nature, will have an impact on results
of operations and the financial condition of Algeta. There are a number of
factors that could cause actual results and developments to differ materially
from those expressed or implied by these forward-looking statements. Theses
factors include, among other things, risks associated with technological
development, the risk that research & development will not yield new products
that achieve commercial success, the impact of competition, the ability to close
viable and profitable business deals, the risk of non-approval of patents not
yet granted and difficulties of obtaining relevant governmental approvals for
new products.
###
This information is subject of the disclosure requirements acc. to §5-12 vphl
(Norwegian Securities Trading Act)
Algeta to Present at Forthcoming Life Sciences Investor Conferences:
http://hugin.info/134655/R/1546257/474401.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Algeta ASA via Thomson Reuters ONE
[HUG#1546257]
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
" alt="Hana Mining: Infill drilling again encounters consistent high-grade copper-silver mineralization along the North Limb of the Banana Zone
Datum: 14.09.2011 - 08:00 Uhr
Sprache: Deutsch
News-ID 64430
Anzahl Zeichen: 6030
contact information:
Town:
Oslo
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 260 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Algeta to Present at Forthcoming Life Sciences Investor Conferences"
steht unter der journalistisch-redaktionellen Verantwortung von
Algeta ASA (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
